share_log

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga ·  Feb 27 12:31

Gainers

  • Janux Therapeutics (NASDAQ:JANX) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap stands at $2.0 billion.
  • Viking Therapeutics (NASDAQ:VKTX) shares moved upwards by 91.96% to $73.87. The company's market cap stands at $7.4 billion.
  • CytomX Therapeutics (NASDAQ:CTMX) shares moved upwards by 41.81% to $2.34. The company's market cap stands at $156.7 million.
  • Biora Therapeutics (NASDAQ:BIOR) shares rose 33.24% to $1.4. The market value of their outstanding shares is at $38.0 million.
  • Codexis (NASDAQ:CDXS) shares increased by 31.4% to $4.21. The company's market cap stands at $293.6 million.
  • Hims & Hers Health (NYSE:HIMS) shares moved upwards by 31.02% to $13.43. The company's market cap stands at $2.8 billion. As per the news, the Q4 earnings report came out yesterday.

Losers

  • Minerva Neurosciences (NASDAQ:NERV) stock decreased by 57.1% to $2.92 during Tuesday's regular session. The market value of their outstanding shares is at $20.4 million. As per the news, the Q4 earnings report came out 3 days ago.
  • NRX Pharmaceuticals (NASDAQ:NRXP) stock declined by 32.77% to $0.29. The company's market cap stands at $24.4 million.
  • Calidi Biotherapeutics (AMEX:CLDI) shares decreased by 24.93% to $0.91. The market value of their outstanding shares is at $32.2 million.
  • Telesis Bio (NASDAQ:TBIO) stock fell 21.22% to $0.52. The company's market cap stands at $15.5 million.
  • Qualigen Therapeutics (NASDAQ:QLGN) shares decreased by 15.21% to $0.49. The company's market cap stands at $2.5 million.
  • SI-BONE (NASDAQ:SIBN) stock decreased by 14.15% to $17.64. The market value of their outstanding shares is at $714.2 million. The company's, Q4 earnings came out yesterday.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment